An effective weight-loss pill to rival injectable drugs like Ozempic and Zepbound might be on the horizon, clinical trial results show.
An experimental GLP-1 pill called orforglipron promoted substantial weight loss without the need for weekly injections, according to final clinical trial results published Tuesday in The New England Journal of Medicine.
Orforglipron also outperformed a tablet form of semaglutide that's already on the market, in both driving weight loss and controlling blood sugar, according to early findings from a head-to-head clinical trial announced by the drug's maker, Eli Lilly and Company.
Based on these findings, Lilly says it plans to submit orforglipron as a weight-loss drug later this year for U.S. Food and Drug Administration review.
Related
